Chemours Company (The) (NYSE:CC) insider E Bryan Snell sold 13,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $49.35, for a total value of $641,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

E Bryan Snell also recently made the following trade(s):

  • On Friday, August 11th, E Bryan Snell sold 10,000 shares of Chemours Company (The) stock. The stock was sold at an average price of $46.24, for a total value of $462,400.00.

Shares of Chemours Company (NYSE:CC) traded up 2.04% on Thursday, reaching $48.94. The company had a trading volume of 2,108,745 shares. Chemours Company has a 52 week low of $12.47 and a 52 week high of $51.51. The company has a market capitalization of $9.04 billion, a P/E ratio of 32.03 and a beta of 3.64. The company has a 50 day moving average of $47.31 and a 200-day moving average of $40.63.

Chemours Company (The) (NYSE:CC) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the firm earned $0.27 earnings per share. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. Analysts predict that Chemours Company will post $3.51 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 17th will be paid a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date of this dividend is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is presently 8.11%.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Chemours Company (The) (CC) Insider Sells 13,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/07/insider-selling-chemours-company-the-cc-insider-sells-13000-shares-of-stock.html.

A number of institutional investors have recently bought and sold shares of CC. BlackRock Inc. raised its stake in Chemours Company (The) by 48,297.2% in the first quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after buying an additional 19,121,339 shares in the last quarter. FMR LLC raised its stake in Chemours Company (The) by 36.6% in the first quarter. FMR LLC now owns 14,925,373 shares of the specialty chemicals company’s stock valued at $574,627,000 after buying an additional 3,998,914 shares in the last quarter. Prudential Financial Inc. raised its stake in Chemours Company (The) by 64.1% in the first quarter. Prudential Financial Inc. now owns 4,473,227 shares of the specialty chemicals company’s stock valued at $172,219,000 after buying an additional 1,747,880 shares in the last quarter. Renaissance Technologies LLC raised its stake in Chemours Company (The) by 135.9% in the first quarter. Renaissance Technologies LLC now owns 3,031,400 shares of the specialty chemicals company’s stock valued at $116,709,000 after buying an additional 1,746,100 shares in the last quarter. Finally, State Street Corp raised its stake in Chemours Company (The) by 35.1% in the first quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock valued at $222,987,000 after buying an additional 1,504,657 shares in the last quarter. Institutional investors own 72.90% of the company’s stock.

Several research analysts have recently commented on CC shares. J P Morgan Chase & Co raised Chemours Company (The) from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $39.00 to $50.00 in a research report on Friday, May 12th. Citigroup Inc. raised Chemours Company (The) from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $43.00 to $45.00 in a research report on Wednesday, July 5th. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price target on shares of Chemours Company (The) in a research report on Friday, June 16th. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Zacks Investment Research lowered Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $51.50.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.